Maxim initiated coverage of Rezolute with a Buy rating and $8 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RZLT:
- Rezolute’s Preclinical Success with New Hypoglycemia Treatment
- Rezolute reports validation of potential use of RZ358
- Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
- Rezolute participates in a conference call with Cantor Fitzgerald
- Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update